Hybrid‐stenting with metallic and bioresorbable drug‐eluting stents 2‐year clinical outcomes in KUM ABSORB registry

Baquet, Moritz; Grundmann, David; Schmidt, Wolfgang A.; Thienel, Manuela; Jochheim, David; Tesche, Christian; Theiß, Hans; Brunner, Stefan; Maßberg, Steffen; Mehilli, Julinda

doi:10.1002/ccd.27832

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these CE marked scaffolds are designed with thicker struts (DESolve, 150 μm; Magmaris, 150 μm; Absorb, 156 μm) as compared with the MeRes100 BRS (100 μm). The thicker strut BRS had higher TLR rates; 7.4% for DESolve, 5.9% for Magmaris, and 7.4% for Absorb when compared with the 1.61% for MeRes100 at 2‐year follow‐up 15,17,22 …”

Section: Discussionmentioning

confidence: 96%

Imaging and 2‐year clinical outcomes of thin strut sirolimus‐eluting bioresorbable vascular scaffold: The MeRes‐1 extend trial

Abizaid

Kedev²,

Ali

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: This study explores the safety and efficacy of thin strut MeRes100 sirolimus-eluting bioresorbable vascular scaffold (BRS) in patients with de novo coronary artery lesions.Background: In interventional cardiology, the emergence of BRS technology is catalyzing the next paradigm shift. Methods:The MeRes-1 Extend was a multicenter, prospective, single-arm, open-label study enrolling 64 patients in Spain, Macedonia, Brazil, South Africa, Malaysia, and Indonesia. The safety endpoint was major adverse cardiac events (MACE) which composed of cardiac death, myocardial infarction (MI), and ischemia-driven target lesion revascularization (ID-TLR). The imaging efficacy endpoint was mean in-scaffold late lumen loss (LLL) evaluated by quantitative coronary angiography (QCA). Optical coherence tomography (OCT) imaging was performed at baseline and 6-month follow-up.Results: A total of 69 target lesions were identified in 64 enrolled patients (mean age 58.30 ± 9.02 years). Of the treated lesions, 49 (71.01%) lesions were of type B2/C. Procedural and device success was achieved in 64 and 62 patients, respectively. At 2-year follow-up, MACE was reported in one patient (1.61%) in the form of

show abstract

Section: Discussionmentioning

confidence: 96%

Imaging and 2‐year clinical outcomes of thin strut sirolimus‐eluting bioresorbable vascular scaffold: The MeRes‐1 extend trial

Abizaid

Kedev²,

Ali

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Lesion impacts on long-term outcomes in patients implanted with bioresorbable vascular scaffold

Wang

Kao

et al. 2022

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Hybrid‐stenting with metallic and bioresorbable drug‐eluting stents 2‐year clinical outcomes in KUM ABSORB registry

Abstract: Despite differences in clinical and angiographic profile, Hybrid-stenting performed similar to BVS alone at 2 years after percutaneous coronary intervention.

Cited by 2 publications

References 26 publications

Imaging and 2‐year clinical outcomes of thin strut sirolimus‐eluting bioresorbable vascular scaffold: The MeRes‐1 extend trial

Imaging and 2‐year clinical outcomes of thin strut sirolimus‐eluting bioresorbable vascular scaffold: The MeRes‐1 extend trial

Lesion impacts on long-term outcomes in patients implanted with bioresorbable vascular scaffold

Contact Info

Product

Resources

About